• Molecular Partners published the Gordon Research Conference presentation, “Appropriate Targets for RLT? High selectivity vs high expression,” by Daniel Steiner.
• Slides outline Radio-DARPin design to match target biology via optimized binding, systemic half-life, biodistribution, aiming to improve outcomes.
• Updates include bispecific Radio-DARPins, 2-in-1 DuoDARPin formats to address tumor heterogeneity by engaging multiple targets.
• Lead program MP0712 (DLL3) remains in a US Phase 1/2a trial; MP0726 (MSLN) targets membrane-bound MSLN with first human imaging expected this year.
• Presentation available at Scientific Documents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150100OMX_____CNEWS_EN_GNW9762212_en) on July 15, 2026, and is solely responsible for the information contained therein.